Observational studyESMO open2023

Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma.

I Nakayama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.